Personnel Information

写真a

YOSHIMORI Mayumi


Job title

Project Assistant Professor

Campus Career 【 display / non-display

  • 2017.05
    -
    2017.09
    Tokyo Medical and Dental University, Graduate School of Health Care Sciences, Biomedical Laboratory Sciences, Moleculo-genetic Sciences, Laboratory Molecular Genetics of Hematology, Technical Assistant
  • 2017.10
    -
    2018.03
    Tokyo Medical and Dental University, Graduate School of Health Care Sciences, Biomedical Laboratory Sciences, Moleculo-genetic Sciences, Laboratory Molecular Genetics of Hematology, Project Assistant Professor
  • 2018.04
    -
    2019.03
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Biomedical Sciences and Engineering, Division of Biomedical Laboratory Sciences, Department of Laboratory Molecular Genetics of Hematology, Project Assistant Professor
  • 2019.04
    -
    2020.05
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Biomedical Sciences and Engineering, Division of Biomedical Laboratory Sciences, Department of Hematological Therapeutics, Project Assistant Professor
  • 2020.06
    -
    2021.02
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Biomedical Sciences and Engineering, Division of Biomedical Laboratory Sciences, Department of Hematological Therapeutics, Assistant Professor
  • 2021.03
    -
    Now
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Biomedical Sciences and Engineering, Division of Biomedical Laboratory Sciences, Department of Hematological Therapeutics, Project Assistant Professor

▼display all

 

Published Papers & Misc 【 display / non-display

  1. Yoshimori M, Nishio M, Ohashi A, Tateishi M, Mimura A, Wada N, Saito M, Shimizu N, Imadome KI, Arai A. Interferon-γ Produced by EBV-Positive Neoplastic NK-Cells Induces Differentiation into Macrophages and Procoagulant Activity of Monocytes, Which Leads to HLH. Cancers. 2021.10; 13 (20): ( PubMed, DOI )

  2. Yoshimori Mayumi, Shibayama Haruna, Imadome Ken-Ichi, Kawano Fuyuko, Ohashi Ayaka, Nishio Miwako, Shimizu Norio, Kurata Morito, Fujiwara Shigeyoshi, Arai Ayako. Antineoplastic and anti-inflammatory effects of bortezomib on systemic chronic active EBV infection BLOOD ADVANCES. 2021.04; 5 (7): 1805-1815. ( PubMed, DOI )

  3. Arai Ayako, Takase Hiroshi, Yoshimori Mayumi, Yamamoto Kouhei, Mochizuki Manabu, Miura Osamu. Gene expression profiling of primary vitreoretinal lymphoma CANCER SCIENCE. 2020.04; 111 (4): 1417-1421. ( PubMed, DOI )

  4. Arai Ayako, Takase Hiroshi, Yoshimori Mayumi, Yamamoto Kouhei, Mochizuki Manabu, Miura Osamu. 原発性硝子体網膜リンパ腫の遺伝子発現プロファイル(Gene expression profiling of primary vitreoretinal lymphoma) Cancer Science. 2020.04; 111 (4): 1417-1421. ( ichushi )

  5. Masuda Azuchi, Isobe Yasushi, Sugimoto Koichi, Yoshimori Mayumi, Arai Ayako, Komatsu Norio. Efficient recruitment of c-FLIPL to the death-inducing signaling complex leads to Fas resistance in natural killer-cell lymphoma CANCER SCIENCE. 2020.03; 111 (3): 807-816. ( PubMed, DOI )

  6. Masuda Azuchi, Isobe Yasushi, Sugimoto Koichi, Yoshimori Mayumi, Arai Ayako, Komatsu Norio. ナチュラルキラー細胞リンパ腫においてc-FLIP_Lが細胞死誘導シグナル伝達複合体へと効率的に動員されるとFas抵抗性が生じる(Efficient recruitment of c-FLIPL to the death-inducing signaling complex leads to Fas resistance in natural killer-cell lymphoma) Cancer Science. 2020.03; 111 (3): 807-816. ( ichushi )

  7. Yonese I, Takase H, Yoshimori M, Onozawa E, Tsuzura A, Miki T, Mochizuki M, Miura O, Arai A. CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential. European journal of haematology. 2018.11; 102 (2): 191-196. ( PubMed, DOI )

  8. 吉森 真由美, 新木 春香, 今留 謙一, 呉 詩星, 立石 萌, 小山 高敏, 新井 文子. EBV陽性NK腫瘍細胞は単球系・血管内皮細胞の凝固促進能を活性化しDICの原因となり得る(EBV-NK-cells induce procoagulant activity of monocytic and vascular endothelial cells causing DIC) 臨床血液. 2018.09; 59 (9): 1654. ( ichushi )

  9. 新井 文子, 米瀬 一朗, 高瀬 博, 吉森 真由美, 三木 徹, 望月 學, 三浦 修. 原発性硝子体網膜リンパ腫におけるCD79B Y196変異(CD79B Y196 mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential) 臨床血液. 2018.09; 59 (9): 1494. ( ichushi )

  10. Onozawa E, Shibayama H, Takada H, Imadome KI, Aoki S, Yoshimori M, Shimizu N, Fujiwara S, Koyama T, Miura O, Arai A. STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target. Oncotarget. 2018.07; 9 (57): 31077-31089. ( PubMed, DOI )

  11. Takada Honami, Imadome Ken-Ichi, Shibayama Haruna, Yoshimori Mayumi, Wang Ludan, Saitoh Yasunori, Uota Shin, Yamaoka Shoji, Koyama Takatoshi, Shimizu Norio, Yamamoto Kouhei, Fujiwara Shigeyoshi, Miura Osamu, Arai Ayako. EBV induces persistent NF-kappa B activation and contributes to survival of EBV-positive neoplastic T- or NK-cells (vol 12, e0174136, 2017) PLOS ONE. 2017.08; 12 (8): e0182682. ( PubMed, DOI )

  12. Honami Takada, Ken-Ichi Imadome, Haruna Shibayama, Mayumi Yoshimori, Ludan Wang, Yasunori Saitoh, Shin Uota, Shoji Yamaoka, Takatoshi Koyama, Norio Shimizu, Kouhei Yamamoto, Shigeyoshi Fujiwara, Osamu Miura, Ayako Arai. EBV induces persistent NF-κB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells. PLoS ONE. 2017.03; 12 (3): e0174136. ( PubMed, DOI )

  13. Yoshimori M, Takada H, Imadome K, Kurata M, Yamamoto K, Koyama T, Shimizu N, Fujiwara S, Miura O, Arai A.. P-glycoprotein is expressed and causes resistance to chemotherapy in EBV-positive T-cell lymphoproliferative diseases. Cancer Medicine. 2015.10; 4 (10): 1494-1504. ( DOI )

  14. Jinta M, Imadome K, Komatsu H, Yoshimori M, Kurata M, Fujiwara S, Miura O, Arai A.. L-Asparaginase monotherapy for EBV-positive T/NK lymphoproliferative diseases: A pilot Study. Journal of Medical and Dental Sciences. 2015.03; 62 (1): 1-9. ( DOI )

  15. Yoshimori M, Imadome K, Komatsu H, Wang L, Saitoh Y, Yamaoka S, Fukuda T, Kurata M, Koyama T, Shimizu N, Fujiwara S, Miura O, Arai A.. CD137 expression is induced by Epstein-Barr virus infection through LMP1 in T or NK cells and mediates survival promoting signals. PLoS One . 2014.11; 9 e112564.

  16. Ayako Arai, Ken-Ichi Imadome, Yuko Watanabe, Mayumi Yoshimori, Takatoshi Koyama, Takeharu Kawaguchi, Chiaki Nakaseko, Shigeyoshi Fujiwara, Osamu Miura. Clinical features of adult-onset chronic active Epstein-Barr virus infection: a retrospective analysis. Int. J. Hematol.. 2011.05; 93 (5): 602-609. ( PubMed, DOI )

  17. Mizuho Nonaka, Shin Uota, Yasunori Saitoh, Mayumi Takahashi, Haruyo Sugimoto, Tohti Amet, Ayako Arai, Osamu Miura, Naoki Yamamoto, Shoji Yamaoka. Role for protein geranylgeranylation in adult T-cell leukemia cell survival. Exp. Cell Res.. 2009.01; 315 (2): 141-150. ( PubMed, DOI )

▼display all

Conference Activities & Talks 【 display / non-display

  1. Mayumi Yoshimori, Megumi Tateishi, Ayaka Ohashi, Ayaka Mimura, Ken-Ichi Imadome, Norio Shimizu, Miwako Nishio, Ayako Arai. IFN-γ, which is Produced by EBV-Positive Neoplastic NK-Cells Induces Macrophage Differentiation and Upregulates Blood Coagulation of which Both Causing HLH.. 2021.07.29

  2. 吉森 真由美, 立石 萌, 大橋 彩香, 呉 詩, 今留 謙一, 清水 則夫, 西尾 美和子, 新井 文子. EBV陽性NK腫瘍細胞は単球からマクロファージへの分化を誘導し,HLHの原因となり得る. 第82回日本血液学会学術集会 2020.10.10

  3. Mayumi Yoshimori, Megumi Tateishi, Ayaka Ohashi, Shixing Wu, Ken-Ichi Imadome, Norio Shimizu, Miwako Nishio, Ayako Arai. Products of EBV-Positive Neoplastic NK-Cells Induce Differentiation into Macrophages and Procoagulant Activity of Monocytes, which Leads to HLH. Virtual 25th EHA Congress 2020.06.12

  4. Onozawa Erika, Shibayama Haruna, Takada Honami, Imadome Ken-ichi, Aoki Sho, Yoshimori Mayumi, Fujiwara Shigeyoshi, Koyama Takatoshi, Miura Osamu, Arai Ayako. 慢性活動性Epstein-Barrウイルス感染症ではSTAT3が恒常的に活性化し治療標的となりうる(STAT3 is constitutively activated in CAEBV and can be a therapeutic target). 臨床血液 2017.09.01

  5. Tsuzura Akiho, Imadome Ken-ichi, Ouchi Fumihiko, Shibayama Haruna, Ohara Osamu, Imai Kohsuke, Matsuda Go, Onozawa Erika, Yoshimori Mayumi, Koyama Takatoshi, Miura Osamu, Arai Ayako. 慢性活動性EBウイルス感染症におけるAPOBEC3Bの発現亢進(Upregulation of APOBEC3B expression in chronic active Epstein-Barr virus infection). 臨床血液 2017.09.01